Clinical outcomes of uterine arterial chemoembolization with drug-eluting beads for advanced-stage or recurrent cervical cancer

Bi, Yonghua; Wang, Yanli; Zhang, Jianhao; Shi, Xiaonan; Wang, Yang; Xu, Miao; Han, Xinwei; Ren, Jianzhuang

doi:10.1007/s00261-021-03267-6

Cited by 14 publications

(12 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a novel drug-delivering device, DEB-TACE showed a advantage of increased local chemotherapy concentration and sustained release of anti-tumor drugs [14][15][16][17]. Previous studies have indicated that DEB-TACE with Callispheres ® beads (CB) is safe and effective in many types of malignant tumors [18][19][20]. To date, no study reports the application of DEB-TACE using raltitrexed-eluting CB for the treatment of GALM.…”

Section: Introductionmentioning

confidence: 99%

Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis

Jiao

Wang

et al. 2022

World J Surg Onc

Self Cite

View full text Add to dashboard Cite

Background Drug-eluting bead transarterial chemoembolization (DEB-TACE) with Callispheres® beads (CB) is currently used in the treatment of hepatocellular carcinoma. However, clinical data regarding DEB-TACE using raltitrexed-eluting CB for gastrointestinal adenocarcinoma liver metastases (GALM) treatment is limited. We aimed to report the preliminary outcomes of DEB-TACE using CB in unresectable GALM patients. Methods This retrospective study enrolled unresectable GALM patients who were treated with DEB-TACE using raltitrexed-eluting CB from October 2018 to October 2021. Totally, 25 patients, 18 males and 7 females, mean age 66.8±9.5 years, were continuously enrolled. Postoperative treatment response, survival rates, and complication were calculated during the procedure and follow-up. Results Twenty-four patients were technically successful, with a technical success rate of 96.0%. The 3-month overall response rate and disease control rate were 21.7% and 73.9%, and 6-month overall response rate and disease control rate were 30.0% and 65.0%. The median survival time from diagnosis of GALM was 31.3 months. The median survival time and median PFS from first DEB-TACE was 21.3 months (95% confidence interval 9.1–33.5) and 10.7 months (3.7–17.7), respectively. Main adverse events included abdominal pain (36.0%), fever (12.0%), and nausea/vomiting (28.0%) after DEB-TACE. No treatment-related deaths and grade 3 or grade 4 adverse events were observed. Conclusions DEB-TACE using raltitrexed eluting CB was demonstrated as a safe and efficient alternative choice for GALM.

show abstract

Section: Introductionmentioning

confidence: 99%

Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis

Jiao

Wang

et al. 2022

World J Surg Onc

Self Cite

View full text Add to dashboard Cite

show abstract

“…Currently, DEB-TACE has been widely used in the treatment of unresectable carcinoma of substantial organs (e.g. liver 6 , 7 , uterus 8 or lung 9 ) rather than cavity organs such as bladder and digestive tract 3 , 15 . Our results indicated that DEB-TACE using doxorubicin-loaded CB is feasible, safe and showed good short-term efficacy without serious adverse events.…”

Section: Discussionmentioning

confidence: 99%

“…Emulsions of chemotherapeutic drugs and lipiodol were usually used in traditional TACE; however, drugs can neither release slowly nor reside long enough time 2 As a novel drug delivery and embolization system, drug-eluting beads TACE (DEB-TACE) is able to release drugs slowly into the malignant tissue after embolizing the tumor-feeding arteries 3 – 5 . CalliSpheres beads (CB) has been used recently for patients with hepatocellular carcinoma 6 , 7 , uterus 8 or lung 9 . In animal study, CB can effectively and safely embolize porcine renal artery 10 .…”

Section: Introductionmentioning

confidence: 99%

Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads

Shi

Ren

et al. 2022

Sci Rep

Self Cite

View full text Add to dashboard Cite

The safety and efficacy of drug-eluting beads transarterial chemoembolization (DEB-TACE) for unresectable renal cell carcinoma (RCC) still unknown. We aimed to assess the feasibility, safety and clinical efficacy of DEB-TACE with doxorubicin-loaded CalliSpheres beads (CB) in patients with unresectable RCC. Between 2016 and 2020, thirty-five patients with unresectable RCC underwent DEB-TACE with doxorubicin-loaded CB. The objective response rate (ORR) was the primary endpoint, and overall survival (OS) and progression-free survival (PFS) were the secondary endpoints. Fifteen-seven times of DEB-TACE were performed in 35 patients using doxorubicin-loaded (median 60 mg) CB. Fifteen patients underwent an additional session of DEB-TACE, with intervals of 1 to 1.5 months. Twenty-one patients underwent transarterial infusion with cisplatin or oxaliplatin before DEB-TACE. The median follow-up time was 9.0 months (Range 1.8–43.6 months). ORR and DCR were 47.1% and 94.1%, 29.0% and 87.1%, 23.1% and 84.6% respectively at 1-, 3-, and 6- months after DEB-TACE. The median PFS was 21.4 months, and the 3-, 6- and 12- month PFS rates were 84.7%, 73.7% and 62.3%, respectively. The median OS was 24.6 months, and the 3-, 6- and 12- month OS rates were 93.9%, 87.6% and 65.2%, respectively. There were no treatment-related deaths or severe adverse events of grade 3 or more. In conclusion, DEB-TACE with doxorubicin-loaded CB is a safe, feasible and effective palliative treatment option for patients with unresectable RCC.

show abstract

“…Currently, TACE has been emerging as a palliative treatment for many kinds of late-stage carcinomas. By using local infusion of chemotherapeutic drugs at high dosage and embolization of tumor-feeding arteries for nutritional deprivation, TACE can cause tumor to shrink, necrosis, or even disappear (14)(15)(16). Besides, preoperative TACE may be beneficial to distinguish tumor boundaries from normal surrounding tissue and improve the resection rate by decreasing tumor volume and intraoperative bleeding (10), when compared with traditional treatments (17,18).…”

Section: Discussionmentioning

confidence: 99%

Transcatheter arterial chemoembolization is safe and effective for patients with late-stage or recurrent oral carcinoma

Pan

et al. 2022

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

ObjectiveWe reported the long-term outcomes of transcatheter chemoembolization (TACE) for patients with late-stage or recurrent oral carcinoma.MethodsThis retrospective study enrolled 18 patients with late-stage or recurrent oral carcinoma between December 2015 and April 2021. The tumor-feeding artery was catheterized, and cisplatin/oxaliplatin and 5-FU/raltitrexed were infused with embolization using polyvinyl alcohol or gelatin sponge. Computed tomography was performed at about 1, 3, and 6 months after the procedure, and every 6 months after that. During the procedure and follow-up, procedure outcomes, complications, treatment efficacy, and overall survival were analyzed.ResultsA total of 31 sessions of TACE were performed, with a technical success rate of 100%. Of 12 patients combined with oral hemorrhage, two patients showed rebleeding 35 and 37 days later, with a clinical efficiency of hemostasis of 88.9%. Mild complications were observed in 11 patients (61.1%). Severe complications or procedure-related deaths were not observed during or after the procedure. The objective response rate and disease control rate were 20.0% and 86.7%, 38.5% and 61.5%, and 25.0% and 50.0% at 1, 3, and 6 months later, respectively. Seventeen patients (94.4%) were followed up, with a median duration of 37.8 months (IQR 22.3–56.8). Nine patients died of tumor progression, one died of massive rebleeding, and one died of severe lung infection. The median overall survival was 23.8 months.ConclusionTACE is a safe and effective procedure with minimal invasiveness for treating late-stage or recurrent oral carcinoma. TACE can be recommended as a palliative treatment, particularly for patients with oral hemorrhage.

show abstract

Clinical outcomes of uterine arterial chemoembolization with drug-eluting beads for advanced-stage or recurrent cervical cancer

Cited by 14 publications

References 20 publications

Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis

Preliminary outcomes of raltitrexed eluting bead-transarterial chemoembolization using Callispheres® beads for gastrointestinal adenocarcinoma liver metastasis

Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads

Transcatheter arterial chemoembolization is safe and effective for patients with late-stage or recurrent oral carcinoma

Contact Info

Product

Resources

About